Literature DB >> 23399693

Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?

Jasvinder A Singh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23399693      PMCID： PMC3899695          DOI： 10.1038/nrrheum.2013.20

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers.

Authors:  N A Obuchowski; R J Graham; M E Baker; K A Powell
Journal:  AJR Am J Roentgenol       Date:  2001-06       Impact factor: 3.959

2.  The allopurinol hypersensitivity syndrome.

Authors:  H J Pluim; M van Deuren; J F Wetzels
Journal:  Neth J Med       Date:  1998-03       Impact factor: 1.422

3.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

4.  Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

Authors:  Issam Zineh; Padmaja Mummaneni; Jenna Lyndly; Shashi Amur; Lois A La Grenade; Stephen H Chang; Hobart Rogers; Michael A Pacanowski
Journal:  Pharmacogenomics       Date:  2011-12       Impact factor: 2.533

5.  Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Authors:  M S Hershfield; J T Callaghan; W Tassaneeyakul; T Mushiroda; C F Thorn; T E Klein; M T M Lee
Journal:  Clin Pharmacol Ther       Date:  2012-10-17       Impact factor: 6.875

6.  Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Authors:  Lisa K Stamp; William J Taylor; Peter B Jones; Jo L Dockerty; Jill Drake; Christopher Frampton; Nicola Dalbeth
Journal:  Arthritis Rheum       Date:  2012-08

Review 7.  The DRESS syndrome: a literature review.

Authors:  Patrice Cacoub; Philippe Musette; Vincent Descamps; Olivier Meyer; Chris Speirs; Laetitia Finzi; Jean Claude Roujeau
Journal:  Am J Med       Date:  2011-05-17       Impact factor: 4.965

8.  Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.

Authors:  Wichittra Tassaneeyakul; Thawinee Jantararoungtong; Pei Chen; Pao-Yu Lin; Somsak Tiamkao; Usanee Khunarkornsiri; Pachadaporn Chucherd; Parinya Konyoung; Suda Vannaprasaht; Charoen Choonhakarn; Pornrith Pisuttimarn; Alisara Sangviroon; Wongwiwat Tassaneeyakul
Journal:  Pharmacogenet Genomics       Date:  2009-09       Impact factor: 2.089

9.  Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.

Authors:  Nicola Dalbeth; Lisa Stamp
Journal:  Semin Dial       Date:  2007 Sep-Oct       Impact factor: 3.455

10.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.

Authors:  Sima Halevy; Pierre-Dominique Ghislain; Maja Mockenhaupt; Jean-Paul Fagot; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Luigi Naldi; Ariane Dunant; Cecile Viboud; Jean-Claude Roujeau
Journal:  J Am Acad Dermatol       Date:  2007-10-24       Impact factor: 11.527
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.